These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 29230493)

  • 1. The limitations of some European healthcare databases for monitoring the effectiveness of pregnancy prevention programmes as risk minimisation measures.
    Charlton RA; Bettoli V; Bos HJ; Engeland A; Garne E; Gini R; Hansen AV; de Jong-van den Berg LTW; Jordan S; Klungsøyr K; Neville AJ; Pierini A; Puccini A; Sinclair M; Thayer D; Dolk H
    Eur J Clin Pharmacol; 2018 Apr; 74(4):513-520. PubMed ID: 29230493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementation of the harmonized EU isotretinoin Pregnancy Prevention Programme: a questionnaire survey among European regulatory agencies.
    Crijns I; Straus S; Luteijn M; Gispen-de Wied C; Raine J; de Jong-van den Berg L
    Drug Saf; 2012 Jan; 35(1):27-32. PubMed ID: 22050373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compliance with pregnancy prevention programmes of isotretinoin in Europe: a systematic review.
    Crijns HJ; Straus SM; Gispen-de Wied C; de Jong-van den Berg LT
    Br J Dermatol; 2011 Feb; 164(2):238-44. PubMed ID: 20716214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare professional surveys to investigate the implementation of the isotretinoin Pregnancy Prevention Programme: a descriptive study.
    Crijns I; Mantel-Teeuwisse A; Bloemberg R; Pinas E; Straus S; de Jong-van den Berg L
    Expert Opin Drug Saf; 2013 Jan; 12(1):29-38. PubMed ID: 23163396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Isotretinoin (Roaccutane) in women of childbearing age: failure of following prescription guidelines].
    Autret E; Radal M; Jonville-Béra AP; Goehrs JM
    Ann Dermatol Venereol; 1997; 124(8):518-22. PubMed ID: 9740842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prenatal exposure to teratogenic medications in the era of Risk Evaluation and Mitigation Strategies.
    Sarayani A; Albogami Y; Thai TN; Smolinski NE; Patel P; Wang Y; Nduaguba S; Rasmussen SA; Winterstein AG
    Am J Obstet Gynecol; 2022 Aug; 227(2):263.e1-263.e38. PubMed ID: 35032444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin-exposed pregnancies: evaluation of the accutane SMART program.
    Brinker A; Kornegay C; Nourjah P
    Arch Dermatol; 2005 May; 141(5):563-9. PubMed ID: 15897377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of 2018 EU Risk Minimisation Measures and Revised Pregnancy Prevention Programme on Utilisation and Prescribing Trends of Medicinal Products Containing Valproate: An Interrupted Time Series Study.
    Abtahi S; Pajouheshnia R; Durán CE; Riera-Arnau J; Gamba M; Alsina E; Hoxhaj V; Andersen M; Bartolini C; Kristiansen SB; Brown J; Hallgreen CE; Garcia-Poza P; Gardarsdottir H; Gini R; Girardi A; Holthuis E; Huerta C; Ibánez L; Limoncella G; Martín-Pérez M; Paoletti O; Roberto G; Souverein P; Swart KMA; Wing K; Sturkenboom M; Klungel O
    Drug Saf; 2023 Jul; 46(7):689-702. PubMed ID: 37294532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiepileptic drug prescribing before, during and after pregnancy: a study in seven European regions.
    Charlton R; Garne E; Wang H; Klungsøyr K; Jordan S; Neville A; Pierini A; Hansen A; Engeland A; Gini R; Thayer D; Bos J; Puccini A; Nybo Andersen AM; Dolk H; de Jong-van den Berg L
    Pharmacoepidemiol Drug Saf; 2015 Nov; 24(11):1144-54. PubMed ID: 26272314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of compliance with isotretinoin PPP recommendations and exploration of reasons for non-compliance: Survey among French-speaking health care professionals and patients in Belgium.
    Lelubre M; Hamdani J; Senterre C; Amighi K; Peres M; Schneider MP; Bugnon O; De Vriese C
    Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):668-673. PubMed ID: 29726056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Be smart, be safe, be sure". The revised Pregnancy Prevention Program for women on isotretinoin.
    Perlman SE; Leach EE; Dominguez L; Ruszkowski AM; Rudy SJ
    J Reprod Med; 2001 Feb; 46(2 Suppl):179-85. PubMed ID: 11255826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the availability of the teratogenic drug isotretinoin outside the pregnancy prevention programme: a survey of e-pharmacies.
    Lagan BM; Dolk H; White B; Uges DR; Sinclair M
    Pharmacoepidemiol Drug Saf; 2014 Apr; 23(4):411-8. PubMed ID: 24493556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continued occurrence of Accutane-exposed pregnancies.
    Honein MA; Paulozzi LJ; Erickson JD
    Teratology; 2001 Sep; 64(3):142-7. PubMed ID: 11514944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ethical challenges of pregnancy prevention programs.
    Bonebrake R; Casey MJ; Huerter C; Ngo B; O'Brien R; Rendell M
    Cutis; 2008 Jun; 81(6):494-500. PubMed ID: 18666392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Healthcare databases in Europe for studying medicine use and safety during pregnancy.
    Charlton RA; Neville AJ; Jordan S; Pierini A; Damase-Michel C; Klungsøyr K; Andersen AM; Hansen AV; Gini R; Bos JH; Puccini A; Hurault-Delarue C; Brooks CJ; de Jong-van den Berg LT; de Vries CS
    Pharmacoepidemiol Drug Saf; 2014 Jun; 23(6):586-94. PubMed ID: 24664855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isotretinoin use and compliance with the Dutch Pregnancy Prevention Programme: a retrospective cohort study in females of reproductive age using pharmacy dispensing data.
    Teichert M; Visser LE; Dufour M; Rodenburg E; Straus SM; De Smet PA; Stricker BH
    Drug Saf; 2010 Apr; 33(4):315-26. PubMed ID: 20297863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Isotretinoin: compliance with recommendations in childbearing women].
    Bensouda-Grimaldi L; Jonville-Béra AP; Mouret E; Elefant E; Dhellot H; Delmas C; Gouin T; Coste P; Autret-Leca E;
    Ann Dermatol Venereol; 2005 May; 132(5):415-23. PubMed ID: 15988352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Exposure to isotretinoin during pregnancy in France: 25 years of follow-up].
    Rouzès A; Jonville-Béra AP
    Therapie; 2014; 69(1):53-63. PubMed ID: 24698189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pregnancy-prevention program in women of childbearing age receiving isotretinoin.
    Mitchell AA; Van Bennekom CM; Louik C
    N Engl J Med; 1995 Jul; 333(2):101-6. PubMed ID: 7777014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the 2018 revised Pregnancy Prevention Programme by the European Medicines Agency on the use of oral retinoids in females of childbearing age in Denmark, Italy, Netherlands, and Spain: an interrupted time series analysis.
    Durán CE; Riera-Arnau J; Abtahi S; Pajouheshnia R; Hoxhaj V; Gamba M; Alsina E; Martin-Perez M; Garcia-Poza P; Llorente-Garcia A; Gonzalez-Bermejo D; Ibánez L; Sabaté M; Vidal X; Ballarín E; Sanfélix-Gimeno G; Rodríguez-Bernal C; Peiró S; García-Sempere A; Sanchez-Saez F; Ientile V; Ingrasciotta Y; Guarneri C; Tanaglia M; Tari M; Herings R; Houben E; Swart-Polinder K; Holthuis E; Huerta C; Gini R; Roberto G; Bartolini C; Paoletti O; Limoncella G; Girardi A; Hyeraci G; Andersen M; Kristiansen SB; Hallgreen CE; Klungel O; Sturkenboom M
    Front Pharmacol; 2023; 14():1207976. PubMed ID: 37663263
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.